ABSTRACT
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04434248
Funding Statement
This project is supported financially by the Russian Direct Investment Fund, the Ministry of Industry and Trade of the Russian Federation and The Skolkovo Innovation Center. Development, manufacturing, and marketing of the investigational product used in this study was provided by ChemRar group of companies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ministry of Health of the Russian Federation
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Manuscript has been revised based on the review provided by members of the Editorial Board of Clinical Infectious Diseases and by specialists in this field . Title revised. Sections updated for clarity. Some figures updated based on the latest data available. Supplemental data file added.
Data Availability
N/A
